Abstract:BackgroundPortal hypertension is a key complication of portal hypertension, which is responsible for the development of varices, ascites, bleeding, and hepatic encephalopathy, which, in turn, cause a high mortality and requirement for liver transplantation.AimThis review deals with the present day state-of-the-art preventative treatments of portal hypertension in cirrhosis according to disease stage. Two main disease stages are considered, compensated and decompensated cirrhosis, the first having good prognosis and being mostly asymptomatic, and the second being heralded by the appearance of bleeding or non-bleeding complications of portal hypertension.ResultsThe aim of treatment in compensated cirrhosis is preventing clinical decompensation, the more frequent event being ascites, followed by variceal bleeding and hepatic encephalopathy. Complications are mainly driven by an increase of hepatic vein pressure gradient (HVPG) to values ≥10 mmHg (defining the presence of Clinically Significant Portal Hypertension, CSPH). Before CSPH, the treatment is limited to etiologic treatment of cirrhosis and healthy life style (abstain from alcohol, avoid/correct obesity…). When CSPH is present, association of a non-selective beta-blocker (NSBB), including carvedilol should be considered. NSBBs are mandatory if moderate/large varices are present. Patients should also enter a screening program for hepatocellular carcinoma. In decompensated patients, the goal is to prevent further bleeding if the only manifestation of decompensation was a bleeding episode, but to prevent liver transplantation and death in the common scenario where patients have manifested first non-bleeding complications. Treatment is based on the same principles (healthy life style..) associated with administration of NSBBs in combination if possible with endoscopic band ligation if there has been variceal bleeding, and complemented with simvastatin administration (20-40 mg per day in Child–Pugh A/B, 10–20 mg in Child C). Recurrence shall be treated with TIPS. TIPS might be indicated earlier in patients with: 1) Difficult/refractory ascites, who are not the best candidates for NSBBs, 2) patients having bleed under NSBBs or showing no HVPG response (decrease in HVPG of at least 20% of baseline or to values equal or below 12 mmHg). Decompensated patients shall all be considered as potential candidates for liver transplantation.ConclusionTreatment of portal hypertension has markedly improved in recent years. The present day therapy is based on accurate risk stratification according to disease stage.

Management of Portal Hypertension in Patients with Hepatocellular Carcinoma on Systemic Treatment: Current Evidence and Future Perspectives

The portal hypertension syndrome: etiology, classification, relevance, and animal models

New Evidence and Perspectives on the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.

Therapeutic Management of Advanced Hepatocellular Carcinoma: An Updated Review

Interpretation of Portal Hypertensive Bleeding in Cirrhosis:Risk Stratification, Diagnosis and Management:2016 Practice Guidance by the American Association for the Study of Liver Diseases

The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

Emerging Therapeutic Targets for Portal Hypertension

Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma - The Changing Tides

Treatments of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Current Status and Controversy

Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers

Management of portal hypertension in patients receiving atezolizumab-bevacizumab for hepatocellular carcinoma

Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review

Portal hypertension in patients with nonalcoholic fatty liver disease: Current knowledge and challenges

Systemic Management for Advanced Hepatocellular Carcinoma: A Review of the Molecular Pathways of Carcinogenesis, Current and Emerging Therapies, and Novel Treatment Strategies

Current and investigational drugs in early clinical development for portal hypertension

Current Trends and Advancements in the Management of Hepatocellular Carcinoma

Recent advances in treatment strategies for hepatocellular carcinoma with portal vein cancer thrombus

Left-sided portal hypertension: Update and proposition of management algorithm

The Role of Endoscopic Ultrasound in Assessing Portal Hypertension: A State‐of‐the‐Art Literature Review and Evolving Perspectives

Treatment of hepatocellular carcinoma: beyond international guidelines

Clinical Practice Guidelines For the Management of Hepatocellular Carcinoma: A Systematic Review